Tempus Next Oncology

Tempus Next Oncology is an AI-enabled care pathway intelligence platform designed for oncology providers and health systems. Built on Tempus's multimodal data infrastructure, Tempus Next Pathways applies technology, data, and artificial intelligence to enable precision medicine — empowering clinicians to identify and act on the next best step in each cancer patient's care journey.

The platform is purpose-built to surface deep, actionable insights from longitudinal patient data at the point of care, helping providers close gaps in guideline adherence, reduce alert fatigue, and improve outcomes across diverse patient populations.

Core Capabilities

• Identify and contextualize patients in their care journey: AI-enabled solutions surface deep insights from multimodal, longitudinal patient data, including medical imaging data, EHR data, lab results, pathology reports, and clinician notes.
• Surface precision care pathways at the point of care: Tiered and customized notifications consistent with precision medicine guidelines are delivered directly within the physician's workflow, reducing alert fatigue and supporting timely clinical decision-making.
• Track patients for timely follow-up: Patient Tracking functionality supports management of patients with active disease, Patient Lists enable providers to search for specific subsets of patients, and Dashboards provide institution-level visibility into the patient population.
• Monitor notification effectiveness and guideline adoption: Institution-level insights reports are delivered to hospital systems, helping administrators and clinical leaders understand the effectiveness of notifications and track emerging trends in guideline adoption.
• Increase equitable access to care: The platform is designed to support timely and accurate diagnostics, procedures, and therapies for all cancer patients, regardless of socioeconomic status, helping to narrow disparities in care delivery.

Clinical Evidence and Real-World Impact

• Closing the biomarker testing gap in early-stage NSCLC: In a case study at TriHealth Cancer and Blood Institute in Cincinnati, Ohio, compliance with targeted biomarker testing guidelines for resectable stage IB–III non-small cell lung cancer (NSCLC) increased to 100% within 25 weeks of Tempus Next deployment.
• Breast cancer care pathway intelligence: Mercy Health System has implemented Tempus Next to support providers in delivering guideline-directed and personalized breast cancer care, as highlighted in a dedicated webinar on navigating new frontiers in breast cancer care pathways.
• Reducing racial disparities in care: Supporting research demonstrates that AI-enabled care pathway solutions can meaningfully narrow gaps in time-to-follow-up between Black and white patients, improving equity in care delivery across patient populations.

Workflow Integration and Deployment

• Notifications are designed to integrate into existing physician workflows, ensuring that precision medicine guidance reaches clinicians at the moment it is most actionable.
• The platform supports EHR integration, enabling seamless access to patient data and reducing friction in clinical adoption.
• Institution-level dashboards and reporting tools provide health system administrators with ongoing visibility into population health trends and guideline compliance metrics.

Tempus Next Oncology is part of Tempus's broader suite of oncology solutions, which includes genomic profiling, algorithmic tests, digital pathology, and clinical trial matching. The platform is designed for deployment across health systems and academic medical centers seeking to operationalize precision oncology at scale and drive measurable improvements in care quality and equity.